Table 2.
Indication for further investigation | Targeted agent |
Further investigation warranted | Bevacizumab Cediranib Trastuzumab AZD1775 |
Further investigation may be warranted | Pazopanib Sunitinib |
No evidence to support further investigation | Abagovomab Nintedanib Lonafarnib Erlotinib Dasatinib |